Sugi Predict

Sugi Predict / Compounds / SCHEMBL4248088

SCHEMBL4248088

SCHEMBL4248088

C[C@H]1CN(C)CCN1C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.39
▸ MAPT P10636 1/20 0.39
▸ GAA P10253 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ GSK3B P49841 1/20 0.34
▸ DYRK1A Q13627 1/20 0.34
▸ CYP1A2 P05177 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ HSP90AA1 P07900 2/20 0.32
▸ HTR1A P08908 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ CA1 P00915 2/20 0.31
▸ CA2 P00918 2/20 0.31
▸ CA4 P22748 2/20 0.31
▸ CA9 Q16790 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9446411 1.00 TSHR (0.39) TSHRMAPTGAASMN1; SMN2LMNA
SCHEMBL3829548 1.00 TSHR (0.39) TSHRMAPTGAASMN1; SMN2LMNA
Hydrochloric Acid SCHEMBL4246521 0.98 TSHR (0.38) TSHRMAPTGAASMN1; SMN2LMNA
Hydrochloric Acid SCHEMBL21805904 0.98 TSHR (0.38) TSHRMAPTGAASMN1; SMN2LMNA
Hydrochloric Acid SCHEMBL16010588 0.98 TSHR (0.38) TSHRMAPTGAASMN1; SMN2LMNA
Succinic Acid SCHEMBL16009795 0.91 SMN1; SMN2 (0.34) TSHRMAPTGAASMN1; SMN2LMNA
SCHEMBL25212730 0.88 GAA (0.38) TSHRMAPTGAASMN1; SMN2LMNA
SCHEMBL799032 0.83 CYP1A2 (0.43) TSHRMAPTGAASMN1; SMN2LMNA
SCHEMBL357615 0.83 CYP1A2 (0.43) TSHRMAPTGAASMN1; SMN2LMNA
SCHEMBL799196 0.83 CYP1A2 (0.43) TSHRMAPTGAASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113423711-B Thieno [3,2-B ] pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use thereof 建新公司 2024-03-15 — — CN claimed
WO-2009147211-A1 NEW COMPOUNDS V BIOVITRUM AB (PUBL) (SE) 2009-12-10 — — WO claimed
US-20250236608-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-07-24 — — US disclosed
CN-113423711-B Thieno [3,2-B ] pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use thereof 建新公司 2024-03-15 — — CN disclosed
WO-2023196283-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2023-10-12 — — WO disclosed
CN-112996784-B Indole derivatives and their use in medicine 北京越之康泰生物医药科技有限公司 2023-05-30 — — CN disclosed
WO-2022170952-A1 POLYCYCLIC PYRIDAZINONE DERIVATIVE SERVING AS SOS1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 苏州阿尔脉生物科技有限公司 2022-08-18 — — WO disclosed
CN-112996784-A Indole derivatives and their use in medicine 北京越之康泰生物医药科技有限公司 2021-06-18 — — CN disclosed
EP-3727364-A1 CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS Angex Pharmaceutical, Inc. (US) 2020-10-28 — — EP disclosed
CN-108658946-B Novel quinazoline inhibitors 焦玉奇 2020-06-16 — — CN disclosed
US-20200102324-A1 UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE GENZYME CORPORATION 2020-04-02 — — US disclosed
EP-3342770-A1 QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR AstraZeneca AB (SE) 2018-07-04 — — EP disclosed
US-20180016259-A1 QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR ASTRAZENECA AB (SE) 2018-01-18 — — US disclosed
EP-2964638-B1 QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR ASTRAZENECA AB (SE) 2017-08-09 — — EP disclosed
US-9718806-B2 Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor ASTRAZENECA AB (SE) 2017-08-01 — — US disclosed
US-20160340342-A1 QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR ASTRAZENECA AB (SE) 2016-11-24 — — US disclosed
EP-2964638-A1 QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR Astrazeneca AB (SE) 2016-01-13 — — EP disclosed
US-9066979-B2 Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor ASTRAZENECA AB (SE) 2015-06-30 — — US disclosed
WO-2014135876-A1 QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR ASTRAZENECA AB (SE) 2014-09-12 — — WO disclosed
US-20140255428-A1 Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor ASTRAZENECA AB (SE) 2014-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200102324-A1 UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE MAN2B1, GAA, GBA1 TSHR 4649/4885MAPT 607/4885GAA 2/4885
US-20180016259-A1 QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR EGFR, ERBB2, ABL1 TSHR 2224/4885MAPT 4105/4885GAA 1310/4885
US-20250236608-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 TSHR 976/4885MAPT 2806/4885GAA 1195/4885
US-20160340342-A1 QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR EGFR, ABL1, ERBB2 TSHR 2333/4885MAPT 4161/4885GAA 1522/4885
US-20140255428-A1 Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor EGFR, ERBB2, ABL1 TSHR 2349/4885MAPT 4146/4885GAA 1637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.